Search
forLearn
5 / 33 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
learn Thymosin Beta 4
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Research
5 / 1000+ resultsresearch Stem Cell Therapies for Epidermolysis Bullosa Treatment
Stem cell therapies may help improve symptoms and quality of life for people with epidermolysis bullosa.
research Causes and Therapeutic Limitations of Clinical Alopecia and the Advent of Human Pluripotent Stem Cell Follicular Transplantation
Stem cell technology may improve hair loss treatments by providing more effective and personalized options.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Regenerative Capacity of Adipose-Derived Stem Cells Compared with Mesenchymal Stem Cells
Adipose-derived stem cells are promising for regenerative medicine due to their accessibility, versatility, and low risk of immune rejection.
research Autologous Cell-Based Therapy for Male and Female Pattern Hair Loss Using Dermal Sheath Cup Cells: A Randomized Placebo-Controlled Double-Blinded Dose-Finding Clinical Study
DSC cell injections significantly improved hair density and diameter, showing potential as a hair loss treatment.
Community Join
5 / 1000+ resultscommunity Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.